ORCA Therapeutics B.V. is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents (ORCA).

These agents are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells,
while healthy cells are left unharmed. In addition, oncolytic viruses are used as efficient delivery agents to express anti-cancer products at high levels in cancer cells and as anti-cancer vaccines that present cancer antigens to the immune system.

 
 

News

30 September 2009
Orca Therapeutics receives VCN License

read more +
 

11 November 2008
ORCA Therapeutics B.V. receives grant from SenterNovem
read more +

 

Job Opportunities

18 August 2010
Technician R&D

read more +

   

Terms of use | Disclaimer | Contact

© 2009 ORCA Therapeutics B.V. | Photography: Wen L. Dong, PhD